The most significant breakthrough in migraine therapy is the targeting of Calcitonin Gene-Related Peptide (CGRP). CGRP is a molecule that surges during a migraine attack, causing blood vessels in the brain to dilate and triggering intense inflammation and pain.

In 2026, CGRP-targeted drugs are divided into two main categories: Monoclonal Antibodies (mAbs) for prevention and Gepants for acute relief. Unlike older medications, these drugs are highly specific; they block the CGRP receptor or the molecule itself without constricting blood vessels. This makes them significantly safer for patients with cardiovascular risks who previously could not take traditional migraine medications.